MKMariah M. Kalmin

Mariah M. Kalmin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mariah M. Kalmin has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Framework for the Opioid Use Disorder Cascade of Care: Adaptation and Application for a Large Municipal Health System

    by Mariah M. Kalmin, Christina Crowley, Lia Pak, Colleen M. McCullough, Beth Ann Griffin, Kyle Ragins, Hrishikesh Belani, Katherine E. Watkins

    Objectives: Most people with opioid use disorder (OUD) do not receive effective treatments despite their existence. The OUD cascade of care framework can be used to inform quality improvement efforts to address this gap, but data access and linkage requirements may limit its use. We sought to adapt the framework under the constraints of electronic health record data and identify patient populations at risk for OUD treatment discontinuity. Materials and Methods: We extracted data on patients with OUD from the Los Angeles County Department of Health Services from July 2022 through June 2023. We adapted the cascade of care to include probable OUD diagnosis, receipt of naloxone prescription, and receipt of ≥1 and ≥2 buprenorphine prescriptions. We then stratified and conducted statistical analyses for associations by sex, race and ethnicity, and facility type (inpatient, primary care, emergency, or urgent care). Results: Of 3881 patients identified with probable OUD, 49% received a naloxone prescription and 30% and 17% had ≥1 and ≥2 buprenorphine prescriptions, respectively, in 1 year. Non-Hispanic Black and Hispanic patients were less likely to receive buprenorphine prescriptions than were non-Hispanic White patients and patients of other or unknown race and ethnicity. We observed larger gaps in care between receipt of ≥1 and ≥2 buprenorphine prescriptions for patients using urgent care and emergency departments compared with patients in other settings. Practice Implications: This study illustrates substantial gaps between OUD diagnosis and treatment. This adapted framework for the OUD cascade of care can serve as a quality-monitoring tool to aid clinicians and health care administrators in narrowing the treatment gap for people with OUD.

  • Open Access

    Clinical Management of Medication-Assisted Treatment for Opioid Use Disorder Using a Mobile Health App Within a Primary Care Clinic: Quasi-Experimental Study

    by Allison D Rosen, Steven J Shoptaw, Li Li, Bengisu Tulu, Omar Nieto, Steven Jenkins, Mariah M Kalmin

    Background: Medication-assisted treatment (MAT) is an effective strategy for treating opioid use disorder and reducing opioid-related overdose deaths, yet retention in treatment remains low. Mobile health (mHealth) platforms may be a useful tool for increasing long-term engagement in MAT programs, but evaluation studies of such platforms are limited. Objective: This study aimed to determine whether the use of the Opioid Addiction Recovery Support (OARS) software platform increased MAT engagement for patients with opioid use disorder. Methods: The Technology Improving Success of Medication-Assisted Treatment in Primary Care Study was a quasi-experimental study conducted at a primary care clinic in the United States between January 2021 and February 2022. OARS is a software platform and mobile app (Q2i, LLC) that includes a dashboard of real-time appointment attendance, urine toxicology (UTOX) results, and educational content as well as messaging and journaling features. All patients who were invited to use OARS and had available data across the study were included in the analysis. The primary outcomes were engagement in treatment, defined as no more than a 35-day gap in appointment attendance, and UTOX. Changes in treatment engagement between the treatment as usual (TAU) period and OARS intervention period were assessed using the effect size (Cohen g) and McNemar chi-square test of discordant pairs. Results: Among 205 patients invited to use OARS, 123 had available data and were thus included in the analysis. The median age was 37 (IQR 31‐42.5 ) years, 61% (75/123) identified as men, and 95.1% (117/123) identified as non-Hispanic White. There were no statistically significant differences in demographic characteristics for patients who used OARS on more than 1 day compared to patients who used OARS on 0 or 1 day, or patients who did versus did not have available data. Among all patients, 20% (25/123) were engaged in appointment attendance during TAU only compared to 27% (33/123) during OARS only (g=0.07; P=.36), and 13% (16/123) were engaged in UTOX during TAU only and 33% (41/123) during OARS only (g=0.21; P≤.01). Among a subsample of 52 patients who used OARS on more than 1 day, 17% (9/52) were engaged in appointment attendance during TAU only compared to 23% (12/52) during OARS only (g=0.07, P=.67), and 13% (7/52) were engaged in UTOX during TAU only and 35% (18/52) during OARS only (g=0.22, P=.05). Conclusions: Introduction of OARS in a primary care setting may be associated with a moderate change in MAT engagement as measured by UTOX, but not appointment attendance. While barriers to implementation and adoption, including difficulty fully integrating OARS with the clinic’s electronic health record, may have attenuated the potential effect of the intervention, this study provides evidence that mHealth interventions, such as OARS, are a promising addition to the MAT treatment landscape.


  • Open Access

    Facilitators and Challenges to Adoption of a Digital Health Tool for Opioid Use Disorder Treatment in Primary Care: Mixed Methods Study

    by Omar Nieto, Allison D Rosen, Mariah M Kalmin, Li Li, Steven J Shoptaw, Steven P Jenkins, Zahra Zarei Ardestani, Bengisu Tulu

    Background: The United States is facing an opioid overdose epidemic resulting in an unprecedented number of preventable deaths. The use of medications including buprenorphine and methadone has proven effective for opioid use disorder (OUD), but many patients struggle to stay in treatment. Novel solutions, such as digital health tools, offer one option to help improve clinic management and improve treatment engagement. Objective: Using a mixed methods approach, we investigated facilitators and barriers to the use of a third-party digital health platform called Opioid Addiction Recovery Support (OARS) to aid OUD treatment engagement and adherence in a primary care setting. Methods: Patient and provider use of OARS was observed for 10 months and summarized using descriptive statistics. Differences in use were assessed using Wilcoxon signed rank tests. Additionally, key informant interviews were conducted with providers who prescribe medication for opioid use disorder (MOUD) and their case managers to understand the facilitators and barriers to implementation. Qualitative data were analyzed using a coding reliability thematic analysis approach. Results: Among 205 patients invited to use OARS, the median age was 37 (IQR 31-44) years, 130 (63.4%) identified as men, and 193 (94.1%) identified as non-Hispanic White. Of these 205 patients, 158 (77.1%) used the app at least 1 time. The median number of days the 158 patients viewed test results was 1 (IQR 1‐3), progress was 1 (IQR 0‐2), and educational content was 0 (IQR 0‐1). The 55 patients whose providers had manually entered their results into OARS when the electronic health record (EHR) integration failed viewed test results (P=.002), progress (P<.001), and educational content (P<.001) more days than the 103 patients who could not view their results in OARS. Providers and the lead case manager reported that OARS increased patient-provider communication, allowed patients to better track their overall MOUD treatment, and enhanced providers’ ability to identify patients at risk for relapse. They also acknowledged that the lack of integration between OARS with the EHR resulted in administrative burdens, which impacted provider use of the system. Conclusions: Findings from this study highlight the challenges of successfully implementing OARS with patients who receive MOUD in primary care settings. Our results show a lack of OARS uptake among providers, case managers, and patients, despite positive assessments made by participants. We also show several barriers that impacted provider use, including the lack of integration between OARS and EHR. Future research is needed (1) to determine whether digital health tools like OARS are efficacious in improving OUD outcomes and, if proved efficacious, (2) to identify ways to routinize the use of digital health tools in MOUD treatment, primarily by solving technical and organizational challenges associated with EHR integration and patient engagement.


  • A Systematic Review of the Efficacy of Contingency Management for Substance Use Disorders in Low and Middle Income Countries

    by Mariah M. Kalmin, Candice Nicolo, Wahbie Long, David Bodden, Lara Van Nunen, Steven Shoptaw, Jonathan Ipser

    Background The impact of illicit substance use is especially devastating in low-resourced countries where factors such as poverty, unemployment, and inadequate services impede successful treatment. Contingency management (CM) is a treatment for substance use disorders that has shown to be effective in eliciting behaviour change. The efficacy of CM interventions in low and middle income countries (LMICs) has been under explored. Methods The aim of this systematic review of randomized controlled trials was to assess measures of CM efficacy in addressing substance use disorders, while also considering contextual moderators of CM in LMICs. A search of PubMed, Scopus, and Cochrane library databases yielded 18 studies for inclusion, from which relevant data were extracted using modified versions of the Cochrane Characteristics of Studies tool. Results Two studies were located in a low-income country, two in lower-middle income countries, and fourteen in upper middle-income countries. Overall, estimated efficacy estimates were similar to those from higher income countries. However, context-specific challenges that warrant further investigation included limited access to trained staff and structural and financial constraints. Conclusions While CM in LMICs is in its early stages of development, efficacy estimates were not substantially different compared to high income countries. Challenges such as costs, willingness to implement, and the stigma associated with addiction sets the stage for further research in these contexts.


  • Incident obstructive lung disease and mortality among people with HIV and a history of injecting drugs

    by Mariah M. Kalmin, Daniel Westreich, Bradley M. Drummond, Jing Sun, Shruti H. Mehta, Gregory D. Kirk

    Objective: People with HIV (PWH) experience increased prevalence of obstructive lung disease (OLD), regardless of greater observed smoking behaviors. We investigated whether the effect of incident OLD on mortality differed by HIV and HIV viral suppression among persons who inject drugs (PWID) and report smoking history. Design: ALIVE is a longitudinal, observational cohort study of HIV-positive and seronegative PWID. This analysis included participants who had at least one spirometry measure to assess OLD between 2007 and 2016, excluding those who never smoked (5%, n = 62) or had baseline OLD (17%, n = 269). Methods: Incident OLD occurred when the first prebronchodilator forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) less than 0.70 during follow-up. The effect of incident OLD on all-cause mortality was estimated in PWH and seronegative participants using inverse-probability-of-treatment-weighted marginal structural models controlling for baseline (age, race, sex, calendar year, smoking pack-years) and time-varying (smoking intensity, viral suppression, and calendar time) confounders. Results: Among 1204 participants, 269 (22.3%) and 157 (13.0%) experienced incident OLD and death, respectively, over a median of five person-years of follow-up. There was no effect of OLD on mortality among seronegative participants [hazard ratio = 0.84, 95% confidence interval (CI): 0.47–1.48]; however, PWH diagnosed with OLD experienced an increased mortality risk (hazard ratio = 1.71, 95% CI: 1.04–2.80) during follow-up. HIV viral suppression did not confound or modify the effect of OLD on mortality among PWH. Conclusion: There was an apparent effect of OLD on all-cause mortality irrespective of viral suppression among PWH but not among seronegative persons, after accounting for baseline and time-varying confounders. These results highlight the need for enhanced screening and management of OLD among PWH.


  • Voting with their feet: Social factors linked with treatment for opioid use disorder using same-day buprenorphine delivered in California hospitals

    by Mariah M. Kalmin, David Goodman-Meza, Erik Anderson, Ariana Abid, Melissa Speener, Hannah Snyder, Arianna Campbell, Aimee Moulin, Steve Shoptaw, Andrew A. Herring


  • Misclassification in defining and diagnosing microcephaly

    by Mariah M. Kalmin, Emily W. Gower, Elizabeth M. Stringer, Natalie M. Bowman, Elizabeth T. Rogawski McQuade, Daniel Westreich

    Background: Several health agencies define microcephaly for surveillance purposes using a single criterion, a percentile or Z‐score cut‐off for newborn head circumference. This definition, however, conflicts with the reported prevalence of microcephaly even in populations with endemic Zika virus.Objective: We explored possible reasons for this conflict, hypothesising that the definition of microcephaly used in some studies may be incompletely described, lacking the additional clinical criteria that clinicians use to make a formal diagnosis. We also explored the potential for misclassification that can result from differences in these definitions, especially when applying a percentile cut‐off definition in the presence of the much lower observed prevalence estimates that we believe to be valid.Methods: We conducted simulations under a theoretical bimodal distribution of head circumference. For different definitions of microcephaly, we calculated the sensitivity and specificity using varying cut‐offs of head circumference. We then calculated and plotted the positive predictive value for each of these definitions by prevalence of microcephaly.Results: Simple simulations suggest that if the true prevalence of microcephaly is approximately what is reported in peer‐reviewed literature, then relying on cut‐off‐based definitions may lead to very poor positive predictive value under realistic conditions.Conclusions: While a simple head circumference criterion may be used in practice as a screening or surveillance tool, the definition lacks clarification as to what constitutes true pathological microcephaly and may lead to confusion about the true prevalence of microcephaly in Zika‐endemic areas, as well as bias in aetiologic studies.